CST, 83405S, Ruxolitinib

Product Usage Information
Ruxolitinib is supplied as a lyophilized powder. For a 15 mM stock, reconstitute 5 mg of powder in 1.09 ml of DMSO. Working concentrations and length of treatment can vary depending on the desired effect.
Storage
Store lyophilized at -20ºC, desiccated. In lyophilized form, the chemical is stable for 24 months. Once in solution, store at -20ºC and use within 3 months to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.
Background
Ruxolitinib, also known as INCB018424, is a potent and selective ATP-competitive inhibitor of Jak1, Jak2, and Jak3 with an IC value of 2.7, 4.5, and 322 nM, respectively (1,2). This small molecule can block IL-6 signaling (IC = 281 nM) and proliferation of Jak2 Ba/F3 cells (IC = 127 nM) (3). The effect that Ruxolitinib has on Jak-signaling leads to the decreased circulation of the proinflammatory cytokines IL-6 and TNF-α, making it an important compound when studying myeloproliferative neoplasms (MPNs) (3). This product has applications to SARS-CoV-2 research into the mechanisms of the Novel Coronavirus, which has caused the COVID-19 pandemic.
Alternate Names
(3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile